Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4,; Investigational Gene Therapy for ND4 LHON (video)

Update Item Information
Identifier 20170404_nanos_sciplatform2_09
Title Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2-ND4,; Investigational Gene Therapy for ND4 LHON (video)
Creator Catherine Vignal, Scott Uretsky, Nitza Thomasson, Céline Bouquet, Anne Galy, Jean Philippe Combal, Serge Fitoussi, Jose Aalin Sahel
Subject Genetic Disease; Optic Neuropathy
Description rAAV2/2-ND4 is an experimental gene therapy enabling allotopic transgene expression. We report visual acuity (VA) outcomes 1.5- years post-treatment in a Phase I/IIa (NCT02064569) open-label, dose-escalation safety study.
Date 2017-04-04
Language eng
Format video/mp4
Source 2017 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2017: Scientific Platform Presentations (Session 2)
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2017. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s60p4tj1
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Contributor Primary Catherine Vignal
Contributor Secondary Scott Uretsky, Nitza Thomasson, Céline Bouquet, Anne Galy, Jean Philippe Combal, Serge Fitoussi, Jose Aalin Sahel
Setname ehsl_novel_nam
ID 1276731
Reference URL https://collections.lib.utah.edu/ark:/87278/s60p4tj1
Back to Search Results